Objective The aim of this study was to investigate the pathophysiology of hospital-acquired pneumonia (HAP) 
Introduction

Hospital-acquired pneumonia (HAP) is the second most common nosocomial infection with the highest mortality rate (1). Since it occurs in patients with underlying diseases that undergo a variety of medical treatments, it is highly likely to be caused by resistant bacteria. Since treatment remains difficult and appropriate antibiotics are essential, the establishment of guidelines for standardizing the management of HAP is necessary. The American Thoracic Society (ATS) published guidelines for the management of HAP in 1996 (2) which were then revised as ATS/Infectious Diseases Society of America (IDSA) Joint Guidelines in 2005 (3). In addition, the Japanese Respiratory Society (JRS) published guidelines for HAP in March 2002 (4). Though the ATS/IDSA guideline (3) excludes patients who are known to be immunosuppressed by human immunodeficiency virus infection, hematologic malignancy, chemotherapy-induced neutropenia, organ transplantation, and so on, the JRS guidelines include the case as pneumonia with specific conditions. In the JRS guidelines, the use of an adequate dosage of potent antibiotics with a broad spectrum of action is recommended, when the causative bacteria has not been iso-
T a b l e 1 . Cl a s s i f i c a t i o n o f t h e S e v e r i t y Ra t i n g o f P n e u mo n i a ( T r a n s l a t e d f r o m J a p a n e s e Re s p i r a t o r y S o c i e t y Gu i d e l i n e s ) lated or identified or if empiric therapy is employed. Following the publication of the JRS guidelines, the validity of the guidelines was examined and reported
and patients were classified according to the guideline criteria (Table 2) .
Clinical response
First-line antibiotics were administered within 3 days of HAP diagnosis, and clinical response was evaluated at the T a b l e 2 . Cl a s s i f i c a t i o n o f P a t i e n t s wi t h Ho s p i t a l -a c q u i r e d P n e u mo n i a end of first line medication. As it is more difficult to objectively assess the efficacy of antimicrobial therapy against HAP compared to community-acquired pneumonia (4) (Fig. 1 ).
Results
Case composition
F i g u r e 1 . Ca s e b r e a k d o wn
T a b l e 3 . P a t i e n t Ch a r a c t e r i s t i c s
Patient characteristics
Cases in hospitals with more than 300 beds accounted for 78.1% (1, Cl i n i c a l E f f i c a c y a n d P r o g n o s i s b y Di s e a s e T y p e 
T a b l e 4 . De t a i l s o f Ca u s a t i v e Or g a n i s ms
T a b l e 6 . De t a i l s o f Cl i n i c a l E f f i c a c y o f F i r s t -l i n e Me d i c a t i o n
Daily dosage of main first-line antibiotics
The maximum daily dosage of main first-line antibiotics for cases of severe pneumonia is shown in T a b l e 9 . F a c t o r s S i g n i f i c a n t l y As s o c i a t e d wi t h P r o g n o s i s i n t h 
T a b l e 7 . De t a i l s o f Ma x i mu m Da i l y Do s e o f F i r s t -l i n e An t i b i o t i c s a g a i n s t S ev e r e P n e u mo n i a
T a b l e 8 . F a c t o r s S i g n i f i c a n t l y As s o c i a t e d wi t h Cl i n i c a l E f f i c a c y o f F i r s t -l i n e An t i b i o t i c s i n t h e Mu l t i p l e L o g i s t i c Re g r e s s i o n An a l y s i s a susceptibility of P. aeruginosa isolates, the minimum inhibitory concentration (MIC)-range, MIC50 and MIC90 of mero-
Analysis of factors affecting efficacy rate/prognosis
Results obtained from multiple logistic regression analysis showed that factors such as complications of malignant tumors had negative effects on the efficacy rate (
e Mu l t i p l e L o g i s t i c Re g r e s s i o n An a l y s i s a
relation to body temperature, the survival rate was lowest in mild cases (!37.5 ) .
Discussion
Multicenter study on HAP in Japan was performed. In this article, patient profiles and prognosis of HAP from 254 institutions were mainly analyzed. The pathophysiology of HAP varies at different medical institutions; for example, its morbidity and mortality are thought to be higher in larger hospitals than in small hospitals (2). This study mainly involved patients in larger hospitals. With regard to HAP prognosis, the mortality rate that is usually reported is 20-50% (1), 50-60% for ICU admissions (6), and 70% in the case of VAP (7). The mortality rate in this study (20%) appeared to be influenced by the fact that there were fewer ICU cases and that the differences in the medical insurance system between the U.S. and Japan resulted in many immunocompetent cases of long-term hospitalization in Japan.
The ATS/IDSA guidelines on HAP define onset in less than 5 days after hospitalization as early onset, and onset after 5 days as late onset (2, 3) . Results from this study showed that early onset cases accounted for less than 10% of cases. Therefore, when using the algorism of the ATS/ IDSA guidelines (3) , most of the cases studied were categorized into the group needing intensive combination antibiotic treatment as empiric therapy. Considering the relatively low mortality rate of HAP in Japan, it is considered to be inappropriate to apply the ATS/IDSA guidelines (3) to HAP of Japan. In the U.S., a number of studies were performed on VAP (8) . There were few cases of VAP in this study, partly because fewer cases were collected from the ICU. In addition, the ratio of aspiration pneumonia was higher in elderly patients. It is generally accepted that aspiration pneumonia, due to inapparent aspiration associated with reduction in swallowing reflex and cough reflex, increases in elderly patients and results of this study appear to confirm these findings.
As for classification by disease type in the JRS guidelines, it is a problem that the 30 day mortality rate significantly varied with severity in the group III pneumonia. Of the pneumonia with specific pathology (group IV), the mortality rate of type E and type F pneumonia was relatively high. As more than 70% of their cause of death is underlying disease, the high mortality rate was considered to be due to the severe clinical condition. Furthermore, clearer status should be given to cases with plural type group IV pneumonia.
Among the laboratory tests used for estimating severity rating in the JRS guidelines, respiratory rate and PaO2 were determined in less than 60% of cases. Therefore, these laboratory data was considered not to be suitable for the severity rating item in the guideline. The criteria for severity rating in the JRS guidelines were settled on the basis of methods (9) , which were made for the efficacy evaluation of trial drugs. Considering that prognosis of patients with pneumonia was the primary end-point, the setting of criteria such as CURB-65 (10) and A-DROP (11) 
